-
2型糖尿病(T2DM)发病机制复杂,目前研究[1]发现和肠道菌群紊乱有关。血浆酪酪肽(peptide YY,PYY),是肠道L细胞分泌的胃肠激素,和胰岛上Y1受体结合抑制胰岛素分泌,改善胰岛素抵抗。肠道菌群能够影响肠激素如胰高血糖素样肽-1(glucagon-like peptide1,GLP1)、胰高血糖素样肽-2(glucagon-like peptide2,GLP2)、PYY的分泌[2]。本研究主要研究双歧杆菌能否降低T2DM大鼠血糖,改善胰岛素抵抗以及对T2DM大鼠血浆PYY产生的影响。
-
高剂量组和低剂量组HbA1c、FBS、FINS、HOMA-IR和TG低于T2DM组(P < 0.01),但高于N组(P < 0.05~P < 0.01);高剂量组和低剂量组PYY高于T2DM组(P < 0.01),但低于N组(P < 0.01),高剂量组和低剂量组上述指标差异均无统计学意义(P>0.05)(见表 1)。
分组 PYY/
(pg/mL)FBS/
(mmol/L)FINS/
(nIU/mL)HOMA-IR HbA1c TC/
(mmol/L)TG/
(mmol/L)LDL/
(mmol/L)HDL/
(mmol/L)N组 0.42±0.06 4.66±0.61 0.14±0.02 0.03±0.01 0.13±0.02 1.55±0.31 0.80±0.12 0.23±0.04 1.08±0.11 T2DM组 0.15±0.01** 14.62±3.43** 0.42±0.12** 0.27±0.12** 0.21±0.02** 2.00±0.17 3.10±0.66** 0.23±0.05 1.09±0.19 低剂量组 0.23±0.02**△△ 9.22±0.94**△△ 0.23±0.03*△△ 0.09±0.01△△ 0.17±0.03*△△ 1.85±0.50 1.29±0.24△△ 0.22±0.05 1.10±0.21 高剂量组 0.23±0.02**△△ 9.55±0.72**△△ 0.23±0.02*△△ 0.10±0.01△△ 0.16±0.02*△△ 1.65±0.23 1.15±0.14△△ 0.27±0.08 0.99±0.30 F 81.87 34.28 24.17 20.24 14.56 2.66 56.43 1.06 0.39 P < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 >0.05 < 0.01 >0.05 >0.05 MS组内 0.001 3.385 0.004 0.004 0.001 0.107 0.132 0.003 0.046 q检验:与N组比较*P < 0.05, **P < 0.01;与T2DM组比较△△P < 0.01 表 1 4组大鼠PYY、FBS、FINS、HOMA-IR、HbA1c和血脂的比较(ni=7; $\overline x \pm s$)
-
对T2DM组、低剂量组、高剂量组大鼠PYY和HOMA-IR水平进行相关性分析显示,二者成负相关关系(r=-0.783,P < 0.01)。
双歧杆菌对2型糖尿病大鼠血浆酪酪肽和胰岛素抵抗的影响
Effect of bifidobacterium on plasma level of peptide YY and insulin resistance in type 2 diabetic rats
-
摘要:
目的观察双歧杆菌对2型糖尿病(T2DM)大鼠血浆酪酪肽(PYY)和胰岛素抵抗指数(HOMA-IR)的影响。 方法30只周龄为9周SD雄性大鼠链脲佐菌素(STZ)造模后,根据双歧杆菌灌胃剂量分成4组:正常对照组(N组)、糖尿病组(T2DM组)、高剂量组和低剂量组,双歧杆菌连续灌胃6周后,测所有大鼠空腹血糖(FBS),处死后取血浆检测PYY、糖化血红蛋白(HbA1c)、空腹胰岛素(FINS)、血脂,计算HOMA-IR,比较4组大鼠上述指标的差异。 结果高剂量组和低剂量组HbA1c、FBS、FINS、HOMA-IR和三酰甘油低于T2DM组(P < 0.01),但高于N组(P < 0.05~P < 0.01);高剂量组和低剂量组PYY高于T2DM组(P < 0.01),但低于N组(P < 0.01),高剂量组和低剂量组上述指标差异均无统计学意义(P>0.05),PYY和HOMA-IR呈负相关(r=-0.783,P < 0.01)。 结论双歧杆菌可以降低T2DM大鼠HbA1c、FBS、FINS、TG和HOMA-IR,升高PYY。 Abstract:ObjectiveTo observe the effects of bifidobacterium on the plasma level of peptide YY (YY) and HOMA-IR in type 2 diabetic(T2DM) rats. MethodsThirty SD male STZ model rats aged 9 weeks were divided into the normal control group(group N), diabetes mellitus group(group T2DM), high dose group and low dose group according to the gavage dose of bifidobacteria.After 6 weeks of continuous bifidobacterium administration, the levels of fasting blood sugar(FBS) were measured in all rats.The serum levels of PYY, HbA1c, fasting insulin(FINS) and blood lipids in four groups were measured after death, the HOMA-IR was calculated to compare the differences of the above indexes among four groups. ResultsThe levels of HbA1c, FBS, FINS, HOMA-IR and triglyceride in high-dose group and low-dose group were significantly lower than those in group T2DM(P < 0.01), and higher than those in group N(P < 0.05 to P < 0.01).The serum levels of PYY in high-dose group and low-dose group were significantly higher than that in group T2DM(P < 0.01), but lower than that in group N(P < 0.01).The differences of the above indictors between high-dose group and low-dose group were not statistically significant(P>0.05), and the level of PYY was negatively correlated with HOMA-IR(r=-0.783, P < 0.01). ConclusionsBifidobacterium can decrease the levels of HbA1c, FBS, FINS, TG and HOMA-IR, and increase the level of PYY in T2DM rats. -
Key words:
- type 2 diabetes mellitus /
- bifidobacterium /
- peptide YY /
- insulin resistance /
- rat
-
表 1 4组大鼠PYY、FBS、FINS、HOMA-IR、HbA1c和血脂的比较(ni=7;
)$\overline x \pm s$ 分组 PYY/
(pg/mL)FBS/
(mmol/L)FINS/
(nIU/mL)HOMA-IR HbA1c TC/
(mmol/L)TG/
(mmol/L)LDL/
(mmol/L)HDL/
(mmol/L)N组 0.42±0.06 4.66±0.61 0.14±0.02 0.03±0.01 0.13±0.02 1.55±0.31 0.80±0.12 0.23±0.04 1.08±0.11 T2DM组 0.15±0.01** 14.62±3.43** 0.42±0.12** 0.27±0.12** 0.21±0.02** 2.00±0.17 3.10±0.66** 0.23±0.05 1.09±0.19 低剂量组 0.23±0.02**△△ 9.22±0.94**△△ 0.23±0.03*△△ 0.09±0.01△△ 0.17±0.03*△△ 1.85±0.50 1.29±0.24△△ 0.22±0.05 1.10±0.21 高剂量组 0.23±0.02**△△ 9.55±0.72**△△ 0.23±0.02*△△ 0.10±0.01△△ 0.16±0.02*△△ 1.65±0.23 1.15±0.14△△ 0.27±0.08 0.99±0.30 F 81.87 34.28 24.17 20.24 14.56 2.66 56.43 1.06 0.39 P < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 >0.05 < 0.01 >0.05 >0.05 MS组内 0.001 3.385 0.004 0.004 0.001 0.107 0.132 0.003 0.046 q检验:与N组比较*P < 0.05, **P < 0.01;与T2DM组比较△△P < 0.01 -
[1] 马苏娴, 张锐锐, 王苏, 等.2型糖尿病患者肠道菌群变化及意义[J].山东医药, 2017, 57(16):20. doi: 10.3969/j.issn.1002-266X.2017.16.006 [2] RHEE SH, POTHOULAKIS C, MAYER EA.Principles and clinical implications of the brain-gut-enteric microbiota axis[J].Nat Rev Gastroenterol Hepatol, 2009, 6(5):306. doi: 10.1038/nrgastro.2009.35 [3] 刘欣欣, 孙华磊, 葛惠娜, 等.紫檀芪对2型糖尿病大鼠学习记忆能力及海马氧化应激水平的影响[J].郑州大学学报(医学版), 2019, 54(1):51. [4] 冯帼, 何柳芳, 刘素丽, 等.双歧杆菌对坏死性小肠结肠炎新生大鼠肠上皮γδT淋巴细胞的影响[J].广东医学, 2016, 37(2l):3177. [5] 陈玲玲, 陆文松, 廖水玉, 等.黄连素对2型糖尿病患者血清炎症因子水平及肠道双歧杆菌的影响[J].中医杂志, 2016, 57(23):2028. [6] 白钰, 吕全胜, 马晓丽.高膳食纤维低血糖生成指数饮食对2型糖尿病患者肠道菌群和血糖的影响研究[J].中国全科医学, 2016, 19(20):2469. doi: 10.3969/j.issn.1007-9572.2016.20.024 [7] BATTERHAM RL, SMALL CJ, COWLEY MA, et al.Gut hormone PYY(3-36) physiologicallyinhibit food intake[J].Nature, 2002, 418:650. doi: 10.1038/nature00887 [8] MATSUDA H, BRUMOVSKY PR, KOPP J, et al.Distribution of neuropeptide Y Y1 receptors in rodent peripheral tissues[J].J Comp Neurol, 2002, 449(4):390. doi: 10.1002/cne.10303 [9] EVERARD A, LAZAREVIC V, DERRIEN M, et al.Responses of gut micro-biota and glucose and lipid metabolism to prebiotics in genetic obese and Diet-Induced Leptin-Resistant mice[J].Diabetes, 2011, 60(11):2775. doi: 10.2337/db11-0227 [10] 梁凤庄.2型糖尿病病人双歧杆菌菌群紊乱对肠道L细胞分泌胰高血糖素样多肽的影响[J].护理研究, 2016, 30(6):2043. [11] 徐宗凯, 王蓉, 杨燕, 等.双歧杆菌对2型糖尿病模型大鼠干预效果观察[J].卫生研究, 2014, 43(2):277. [12] 王蓉, 徐宗凯, 杨燕, 等.双歧杆菌微生态制剂对2型糖尿病模型大鼠炎症反应相关因子和抗氧化体系的影响[J].现代预防医学, 2014, 41(6):1086. [13] AMAR J, CHABO C, WAGET A, et al.Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes:molecular mechanisms and probiotic treatment[J]. EMBO Mol Med, 2011, 3(9):559. doi: 10.1002/emmm.201100159 [14] CHEN J, WANG R, LI XF, et al.Bifidobacterium adolescentis supplementation ameliorates visceral fat accumulation and insulin sensitivity in an experimental model of the metabolic syndrome[J].Br J Nutr, 2012, 107(10):1429. doi: 10.1017/S0007114511004491 [15] TONUCCIA LB, OLBRICH DOS SANTOSKM, LICURSI DE OLIVEIRAL, et al.Clinical application of probiotics in type 2 diabetes mellitus:a randomized, double-blind, placebo-controlled study[J].Clin Nutr, 2015:1.